Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

Abstract

ColoPrint significantly improves the prognostic accuracy of pathologic factors and MSI in patients with stage II and III CRC and facilitates the identification of patients with stage II disease who may be safely managed without chemotherapy.